Anatoly Dritschilo

This inventor holds 24 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Cancer Therapies. Top assignees: Georgetown University, Shuttle Pharmaceuticals, Inc., Neopharm, Inc.. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anatoly Dritschilo. Retrieved from https://idiyas.com/inventor/anatoly-dritschilo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 8)

% Patents Active = 79.2

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 237(Granted Patents)

Location History:

Washington, DC (US) (2003)
Rockville, MD (US) (2017 - 2023)
Bethesda, MD (US) (1996 - 2024)

Company Filing History:

15 out of 499

Georgetown University

patents

9 out of 9

Shuttle Pharmaceuticals, Inc.

University of Illinois

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

Cancer Therapies

Histone Deacetylase Inhibitors

Liposomal Delivery Systems

Radiation Treatments

Gene BRCC-2

Gene BRCC-3

Cationic Liposomes

Oligonucleotides

Dual Function Molecules

Stereotactic Radiosurgery

Chemosensitizing Agents

Anthracycline Encapsulation

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12357650 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation (2025-07-15),

2. 12077515 - Selective histone deacetylase inhibitors for the treatment of human disease (2024-09-03),

3. 11654157 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation (2023-05-23),

4. 11584733 - Selective histone deacetylase inhibitors for the treatment of human disease (2023-02-21),

5. 11407723 - Selective histone deacetylase inhibitors for the treatment of human disease (2022-08-09),

6. 11034667 - Selective histone deacetylase inhibitors for the treatment of human disease (2021-06-15),

7. 10745352 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-18),

8. 10730834 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-04),

9. 9809539 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2017-11-07),

10. 8748463 - Histone deacetylase inhibitors and methods of use thereof (2014-06-10),

11. 8653278 - Isoform selective HDAC inhibitors (2014-02-18),

12. 8293513 - Histone deacetylase inhibitors (2012-10-23),

13. 8222451 - Histone deacetylase inhibitors and methods of use thereof (2012-07-17),

14. 7842835 - Histone deacetylase inhibitors and methods of use thereof (2010-11-30),

15. 7442520 - Gene BRCC-3 and diagnostic and therapeutic uses thereof (2008-10-28),

Title: The Innovative Journey of Anatoly Dritschilo

Introduction: Anatoly Dritschilo, a distinguished inventor based in Bethesda, MD (US), has made significant contributions to the field of innovation and patents.

Latest Patents: Anatoly Dritschilo holds several patents in the medical field, focusing on advancements in cancer treatment and radiation therapy.

Career Highlights: With a career spanning several decades, Dritschilo has been a pioneer in developing cutting-edge technologies for cancer research and treatment. His work has led to groundbreaking discoveries in the fight against cancer.

Collaborations: Throughout his career, Anatoly Dritschilo has collaborated with leading researchers, medical professionals, and institutions to further the impact of his inventions. His collaborative efforts have resulted in the development of innovative solutions with real-world applications.

Conclusion: Anatoly Dritschilo's dedication to innovation and his relentless pursuit of advancements in cancer treatment have solidified his reputation as a visionary inventor in the medical field. His work continues to inspire future generations of inventors and researchers in the fight against cancer.

Profile summary based on public USPTO records.